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Abstract
SAR1 is a new IgG2a murine monoclonal antibody derived by immunization with a plant virus expressing the sequence GERDRDR from
the C-terminal tail of the gp41 transmembrane glycoprotein of human immunodeficiency virus type 1 (HIV-1). SAR1 binds to peptides and
proteins carrying the GERDRDR sequence, to some but not all preparations of purified virus, and to cells infected with all viruses tested.
In a standard neutralization assay, SAR1 failed to neutralize, or neutralized poorly, a number of T cell line-adapted viruses. However, it was
more effective at postattachment neutralization. This was measured by two assays, the inhibition of the syncytium production by input virus,
and the inhibition of the production of infectious progeny virus. In general SAR1 was more effective at neutralizing progeny virus than
inoculum virus. Fifty percent inhibition of progeny virus production by different HIV-1 strains was obtained with 2–26 g/ml of SAR1.
The SAR1 neutralizing epitope was mapped specifically to the gp41 C-terminal tail. SAR1 is an unusual, if not unique, antibody whose
activity supports the view that part of the gp41 C-terminal tail is exposed on the outside of the virion.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
The envelope protein of human immunodeficiency virus
type 1 (HIV-1) is synthesized as a gp160 polypeptide that is
cleaved to form a noncovalently linked heterodimer—an
external gp120 domain and a transmembrane, anchoring
gp41 domain. Virions, which are formed by budding from
the plasma membrane, contain in their envelope the mature
envelope protein. This is composed of a trimer of the het-
erodimer. The trimer attaches virus to CD4 molecules of a
target cell, and promotes fusion of the viral lipid bilayer
with that of the target cell plasma membrane so that the
virus genome can enter the cell cytoplasm and initiate in-
fection. There are approximately 70 trimers per virion (for
a review see Levy, 1998).
In addition to the foregoing functions, the envelope pro-
tein has the important role of interacting with the immune
system of the host, and in particular with neutralizing anti-
bodies. There are four major antibody-binding sites on
gp120 and two on gp41. Sites on gp120 are (a) the third
variable (V3) loop that is recognized by many different
virus strain-specific antibodies (Krachnarov et al., 2001);
(b) a conformational region that overlaps the binding site of
the CD4 primary receptor, and is recognized by MAbs such
as b12 (Barbas et al., 1992); and (c) a conformational,
carbohydrate-dependent site recognized by MAb 2G12
(Trkola et al., 1996). MAbs b12 and 2G12 are highly active
and neutralize viruses from several different clades (Trkola
et al., 1995). Finally, there is (d) the CD4-induced (CD4i)
site that is normally cryptic but is revealed by conforma-
tional changes to gp120 that occur after its interaction with
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CD4 (Thali et al., 1993). CD4i partially overlaps the CCR5
coreceptor-binding site, and is recognized by MAb 17b, a
weakly neutralizing antibody. It has been possible to envi-
sion the relationship of these antigenic sites with the phys-
ical structure of gp120 as a result of the determination of the
crystal structure of the gp120-CD4-FAb 17b complex
(Kwong et al., 1998).
The structure of all or part of the gp41 ectodomain has
also been solved (Chan et al., 1997; Tan et al., 1997;
Weissenhorn et al., 1997; Caffrey et al., 1998; Malash-
kevitch et al., 1998). The ectodomain supports a conforma-
tional antigenic site that is recognized by the cross-clade
neutralizing MAb 2F5 (Muster et al., 1993). In addition
there is an antigenic site, within the sequence 731PRGPDR-
PEGIEEEGGERDRDRS752, which is situated in the long
(approximately 150-residue) C-terminal tail of gp41 (Chanh
et al., 1986). This contains three epitopes: 734PDRPEG739, a
linear epitope recognized in Western blots by MAb C8
(Abacioglu et al., 1994) but present in the virions of a
neutralization escape mutant selected by antibody to an
adjacent epitope (McLain et al., 2001); 740IEEE743 a linear
epitope recognized by MAb 1575; and 746ERDRD750, a
conformational epitope recognized by MAb 1577 (Vella et
al., 1993). None of these MAbs is intrinsically neutralizing,
but MAb 1577 mediates neutralization in conjunction with
complement (Cleveland et al., 2003). However, polyclonal
neutralizing antibodies have been reproducibly raised by
immunization with plant virus chimeras that express resi-
dues 731–752 or 745–751 (Buratti et al., 1998; Cleveland et
al., 2000a). These antibodies are specific for ERDRD as
shown by adsorption to and elution from fusion proteins
expressing the relevant epitope. While the C-terminal tail of
gp41 is conventionally viewed as residing inside the virion,
we have argued that since antibodies do not cross lipid
membranes yet neutralize infectious (i.e. intact) virus par-
ticles, at least some gp41 molecules have part of their
C-terminal tail exposed on the outside of the virion (Cleve-
land et al., 2003).
In this report we describe a new monoclonal antibody,
SAR1, specific for the HIV-1 gp41 tail sequence GER-
DRDR, which actively neutralized virus after it had attached
to target cells but had little activity against free virions. This
antibody may be unique in that its greatest antiviral effect is
inhibition of the production of infectious progeny virions.
The data also suggest that it might be useful to screen all
potential antiviral MAbs for postattachment neutralization
activity.
Results
Preparation of MAbs
Most sera (9/10) from mice immunized with CPMV-
HIV/29 neutralized NL-4.3 to a maximum of 81% at a 1/100
dilution, and 9/10 reacted in ELISA with immobilized flock
house virus S-capsid proteins displaying the gp41 sequences
745GERDRDR751 (FHV-L1-B) or 740IEEEGGERDRDR751
(FHV-L2-A) (data not shown). The best mouse responder
was reimmunized intravenously and splenectomized 4 days
later. Spleen cells were fused with Sp2 myeloma cells and
hybridomas produced by standard methods. Culture fluids
were screened for GERDRDR-specific antibody by reactiv-
ity with FHV-L2-A. Monoclonal cell lines were obtained by
three rounds of limiting dilution. The four most reactive cell
lines secreted IgG2a with kappa light chains.
Weak standard neutralization
Virus and IgG (0.1 to 100 g/ml) from the four hybrid-
omas were incubated together for 1 h at 37°C, and then
inoculated onto C8166 cells for 1 h at 37°C. The inoculum
was then removed, fresh medium was added, and cells were
reincubated for 3 days at 37°C. Neutralization was deter-
mined by counting syncytia. Fig. 1 shows that MAb SAR1
gave a maximum of 50% neutralization of HIV-1 IIIB, but
no significant reduction of HxB-2D or NL-4.3 infectivity.
NL-4.3(R723G) is a neutralization escape mutant selected
by ERDRD epitope-specific polyclonal antibody that has an
altered conformation of its ERDRD epitope (McLain et al.,
2001). This was also not neutralized. Extending the time of
virus-MAb incubation up to 20 h did not increase neutral-
ization. The other hybridomas behaved similarly.
Binding of MAb SAR1 to antigens expressing the ERDRD
epitope
SAR1 bound to CPMV-HIV/1 and CPMV/HIV-29, flock
house virus fusion proteins, and a free Kennedy peptide that
Fig. 1. Standard neutralization of HIV-1 strains by SAR1 IgG. HIV-1 IIIB
(f), HxB-2D (), NL-4.3 (Œ), or NL-4.3(R732G) () were incubated with
SAR1 for 1 h at 37°C, and virus inoculated onto C8166 cells for 1 h at
37°C. Inocula were removed and replaced with fresh medium. Syncytia
were counted at 72 h postinfection. Neutralization is expressed as the
percentage reduction in the number of syncytia compared to that of a
nonneutralized virus control. Data are the mean of five replicates within
individual experiments.
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all contained GERDRDR sequences, but not to wt CPMV
(Fig. 2a). However, when corrected for the molarity of
ERDRD (60 copies per virion for chimeras, and 1 copy per
molecule for each of the flock house virus proteins and the
peptide) and amount of antigen bound, SAR1 bound best to
CPMV-HIV/29 and four times better than to free peptide
(Table 1). SAR1 weakly recognized gp41 in Western blots
of purified IIIB, whereas a control antibody (MAb 1575),
which binds to an adjacent epitope, gave a strong positive
reaction (Fig. 2b). Together these data suggest that the
SAR1 epitope has a degree of conformational dependence.
Fig. 3 shows SAR1 binding to purified virus. SAR1 recog-
nized all preparations of IIIB, HxB-2D, and NL-
4.3(R732G), and some but not all preparations of NL4.3
(data not shown). SAR1 bound 13-fold more to IIIB and
HxB-2D, and 4-fold more to NL-4.3(R732G) than did nor-
mal mouse IgG. A control gp120-specific MAb
(ICR39.13g) bound to all viruses. SAR1 also bound to cells
that had been infected with virus for 3 days. All viruses
tested (IIIB, HxB-2D, NL4.3, and NL-4.3(R732G)) gave a
positive result (Fig. 4).
The variability of binding to NL4.3 particles and the
weak standard neutralization of all viruses tested may indi-
cate that SAR1 binds to noninfectious, rather than infec-
tious, virus particles. Thus some preparations of NL4.3 may
by chance contain too little noninfectious virus to give
significant binding. If our hypothesis is correct, SAR1 can
recognize ERDRD on noninfectious virus particles and cell-
associated gp41, but not ERDRD on infectious virus. The
ERDRD epitope on infectious virus may be in a different
conformation or may be hidden.
Neutralization of virus after its attachment to cells
Virus was incubated with cells for 1 h at room temper-
ature to permit attachment but not virus–cell fusion. After
removal of inoculum, cells were rinsed with medium and
incubated with SAR1 IgG for 3 days at 37°C. We deter-
mined the amount of postattachment neutralization (PAN)
of inoculum virus by the extent of syncytium inhibition, and
the amount of neutralization of infectious progeny (NIP) by
assay of progeny infectivity.
(a) Postattachment neutralization
Fig. 5 shows that PAN titers of IIIB, HxB-2D, and
NL-4.3 were low, with N50 values ranging from 42 to 96
g/ml (Table 2). MN had an N50 of 29 g/ml even though
it has an R751T substitution (Myers et al., 1993), suggesting
that the R751 is not an essential part of the SAR1 epitope.
Interestingly SAR1 gave the best PAN with NL-
4.3(R732G), a neutralization escape mutant that has an
altered conformation of the ERDRD epitope (McLain et al.,
2001), and this required only 2 g/ml for N50. The maxi-
mum PAN (80%) was also achieved with NL-4.3(R732G).
Fig. 2. Binding of SAR1 IgG to parts of the Kennedy sequence of HIV-1 gp41 displayed in a variety of antigen formats. In (a) ELISA reactivity was
determined with the chimeras CPMV-HIV/29 (745GERDRDR751) and CPMV-HIV/1 (731PRGPDRPEGIEEEGGERDRDRS752), the fusion proteins FHV-
L2-A (740IEEEGGERDRDR751) and FHV-L1-B (745GERDRDR751), the gp41 peptide 731PRGPDRPEGIEEEGGERDRDRS752, and wt CPMV that displays
no HIV-1 epitope (not shown). ELISA plates were coated with each chimera, fusion protein, or peptide in approximately equimolar amounts in respect of
ERDRD, and then the actual amount bound was determined. Binding to wt CPMV (5%) has been subtracted. Binding of 10 ng SAR1 per well is shown,
which is in the linear response range, and is normalized for the amount of bound antigen. (b) Western blot of purified HIV-1 IIIB particles with MAb 1575
IgG (left panel) and SAR1 IgG (right panel). Virus loadings were: lanes 1, 8: 1.6  104 sfu; 2, 7: 8  103 sfu; 3, 6: 4  103 sfu; 4, 8: diluent. The Mr of
markers is shown on the side and the positions of gp160 (lane 1, arrow head) and gp41 are indicated.
Table 1
Efficiency of binding of MAb SAR1 per molecule of ERDRDa
ERDRD carrier Efficiency of binding of SAR1 per molecule
of ERDRD (%) relative to CPMV-HIV/29
CPMV-HIV/29 100.0
FHV-L2-A 93.5
CPMV-HIV/1 74.5
FHV-L1-B 61.5
Kennedy peptide 24.5
a Data from Fig. 2a, corrected for the number of molecules of ERDRD
per carrier molecule (60 per virus particle for the CPMV chimeras, and 1
per molecule for each of the FHV fusion proteins and the peptide), and the
amount of antigen bound to the plastic
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(b) Neutralization of infectious progeny
Values for NIP were significantly higher than those for
PAN (by t-test, 95% confidence limits) for IIIB, HxB-2D,
NL-4.3, and MN (Fig. 5). HxB-2D was particularly sensi-
tive, with N50 and N90 values of 2 and 11 g/ml, respec-
tively. There was a maximum of 87% NIP with MN at 30
g/ml. There was the least NIP with NL-4.3(R732G). NIP
Fig. 3. Binding of SAR1 IgG to preparations of purified HIV-1. Virus
particles were purified by centrifugation through a 15–60% sodium potas-
sium tartrate, fixed with paraformaldehyde, and captured with solid-phase
MAb 2F5 (wells coated with 0.1 g). HIV-1 was then incubated with
SAR1 IgG (solid bars), ICR39.13g IgG (hatched bars), or normal mouse
serum IgG (NMS, open bars, 10 g/ml only), and binding determined by
ELISA. Data are the mean of two replicate assays. Error bars are the
standard deviation of the mean.
Fig. 4. Reactivity of SAR1 IgG with C8166 cells infected with strains of
HIV-1. Paraformaldehyde-fixed infected cells (5  104) were incubated with
1 g of IgG from SAR1, 1575, or normal mouse serum (NMS) in a spin-
ELISA format. Infected cells, solid bars; noninfected cells, open bars. Data are
the mean of three replicates. Error bars are the standard deviation of the mean.
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and PAN titers for NL-4.3(R732G) did not differ signifi-
cantly.1
This increased ability of SAR1 to neutralize infec-
tious virus after virus has attached to cells is consistent
with a change in conformation or availability of its ER-
DRD epitope that occurs concomitantly with that attach-
ment.
SAR1 does not mediate PAN of virus that lacks the gp41
C-terminal tail
Although SAR1 reacts with various structures carrying
the GERDRDR sequence, and this sequence is not present
elsewhere in the HIV-1 envelope protein, it was conceivable
that SAR1 neutralizes by binding to another epitope in the
gp120–gp41 trimer. Such an epitope could be a conforma-
tional mimic that has limited or no sequence homology with
GERDRDR. To test this hypothesis we carried out PAN
with HXBH10CT, a virus that has a frameshift mutation
and lacks the 144 C-terminal tail residues of gp41, including
the GERDRDR sequence. Fig. 6 shows that while the parent
virus was neutralized, the infectivity of HXBH10CT was
unaffected by SAR1. The P values for significant levels of
PAN are shown on the figure. Both wt and mutant viruses
were neutralized to the same extent by antibodies that re-
acted with other regions of the other envelope protein (data
not shown). These data establish that the SAR1 epitope is
located in the gp41 tail.
Mapping of the SAR1 epitope by competitive binding
Biotinylated MAb 1575 (specific to epitope IEEE) binds
to FHV-L2-A, a flock house virus protein that has an inter-
nal fusion with the IEEEGGERDRDR sequence from the
C-terminal tail of gp41. Such binding should be inhibited by
1 NIP data are summarized in Table 2.
Table 2
Summary of the standard neutralization (STAN), postattachment
neutralization (PAN), and neutralization of infectious progeny
(NIP) activities of MAb SAR1
STAN N50a PAN NIP
N50 N90 N50 N90
IIIB 100b 96 100 5 90
HxB-2D 100 92 100 2 11
MN 100 29 100 13 100
NL-4.3 100 42 100 12 74
NL-4.3(R732G) 100 2 100 26 100
a N50, N90, 50 and 90% neutralization.
b SAR1 concentrations in g/ml.
Fig. 5. Neutralization by MAb SAR1 after virus has attached to cells. C8166 cells (5 104 cells per replicate) were incubated with virus (50 sfu; IIIB, NL-4.3,
NL-4.3(R732G), HxB-2D, and MN) for 1 h at room temperature. Unattached virus was then removed and SAR1 IgG (3–100 g/ml) added in medium. Cells
were incubated for 3 days. Neutralization is expressed as PAN by the percentage reduction in syncytium number (f), or as NIP by titrating infectious progeny
virus from 72 h TCFs on fresh C8166 cells (Œ). After allowing virus to attach, cells were washed and incubated for 3 days before counting syncytia. For
each assay, the percentage neutralization was calculated relative to that of a virus control without antibody. Data are the mean of five replicates. Error bars
are the standard error of the mean of three independent experiments.
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antibodies that bind to the same epitope or by antibodies
whose footprint overlaps that of IEEE. (A footprint has an
area of 690–916 A˚ 2 (Wilson and Stanfield, 1993)). Indeed
we found that binding of MAb 1575 was competed success-
fully by incubation with MAb 1577, specific to the adjacent
ERDRD sequence (Fig. 7a). MAb SAR1 also inhibited
binding of MAb 1575 to a similar extent, indicating that its
epitope is situated close by the IEEE sequence.
MAb 1575 is nonneutralizing in both STAN and PAN
assay formats (data not shown), and thus could be used to
map the relative position of the functional SAR1 epitope.
Fig. 7b shows a dose–response curve in which MAb 1575
inhibited SAR1-mediated PAN by around 80%. There was
50% reduction of PAN with 0.4 g/ml MAb 1575. Normal
mouse IgG gave no significant inhibition at 100 g/ml. To
check the specificity of this competition neutralization re-
action, MAb 1575 (0.1–100 g/ml) was added to 5 g/ml
2F5, a monoclonal antibody that recognizes an epitope in
the ectodomain of gp41. MAb 1575 had no effect on the
level of 2F5 neutralization, indicating that the competition
observed with SAR1 was specific (data not shown). To-
gether Figs. 7a and b show that MAbs SAR1 and 1575 have
overlapping footprints on the surface of infectious HIV-1.
Discussion
Mapping the SAR1 epitope
MAb SAR1 was made by immunizing mice with a plant
virus expressing the gp41 C-terminal tail sequence 746GER-
DRDR751 and recognized a variety of structures expressing
the GERDRDR epitope. However, it was necessary to ex-
clude the possibility that, when reacting with HIV-1 parti-
cles, SAR1 bound to an epitope mimic sited elsewhere on
the envelope protein, which might have no sequence simi-
larity to GERDRDR. Specificity for the gp41 tail was dem-
onstrated by showing that SAR1 did not neutralize virus that
lacked the C-terminal tail. In addition PAN effected by
SAR1 was blocked by reacting virus with MAb 1575, spe-
cific for the adjacent epitope 740IEEE743, whose footprint
would be expected to overlap the 746GERDRDR751 epitope.
Fig. 6. SAR1 failed to mediate PAN of HIV-1 HXBH10CT, which has a
frameshift mutation and lacks the 144 C-terminal tail residues of gp41 that
includes the GERDRDR sequence, but mediated PAN of the wt HXBH10
virus. C8166 cells were inoculated with HXBH10 and HXBH10CT (50
sfu) for 3 h at room temperature. Cells were washed and SAR1 IgG was
added. Incubation was continued for 3 days and syncytia were counted. wt
HXBH10 (f); HXBH10CT (Œ). Percentage neutralization was calculated
as in Fig. 1. Error bars are the standard deviation of the mean. The figure
shown is representative of two replicate experiments.
Fig. 7. Epitope mapping of MAb SAR1. (a) By competitive binding with MAb 1575 to the fusion protein FHV-L2-A that expresses the gp41 sequence
740IEEEGGERDRDR751. Biotinylated MAb 1575 (0.2 g) was mixed with MAb SAR1 (Œ), MAb 1577 (f), or normal mouse serum () IgG (0.03 to 3.0
g), and incubated for 1 h at 37°C with solid-phase FHV-L2-A (plates previously coated with 0.1 g/well). Bound MAb 1575 was detected with conjugated
streptavidin-alkaline phosphatase. Error bars are the standard deviation of the mean. (b) By competitive binding with MAb 1575 to infectious HIV-1. This
assay measured the reduction in postattachment neutralization (PAN) mediated by MAb SAR1. MAb 1575 is nonneutralizing. C8166 cells were inoculated
with HIV-1 strain NL-4.3 for 1 h at room temperature. MAb SAR1 (100 g/ml) was then added together with MAb 1575 (0 to 100 g/ml) and incubated
for 3 days at 37°C. Syncytia were counted and the inhibition of PAN by MAb 1575 was expressed as the percentage reduction in syncytium inhibition
compared to PAN mediated by MAb SAR1 alone. Data are the mean of five replicates.
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Neutralization of virus infectivity by SAR1
It is not clear why mice immunized with CPMV-HIV/29
had serum antibody levels that gave quite high STAN, but
yielded no MAb with comparable activity. One possibility
is that splenocytes with the potential to make PAN antibody
were more frequent that those that made STAN antibody.
However, had we only used the conventional standard neu-
tralization screen, the SAR1 MAb would not have been
found, and one can only speculate how many MAbs of this
type have been missed in the past. Based on its interaction
with five HIV-1 strains, SAR1 has unusual neutralization
activity. It was almost inactive at STAN, more active at
PAN, and best at NIP. By comparison, MAb b12, for ex-
ample, an IgG to the CD4 binding site, gives excellent
STAN, and very poor PAN and NIP (McInerney and Dim-
mock, 2001; L. McLain and N. J. Dimmock, unpublished
data), while PAN of an influenza virus required a higher
concentration of antibody than STAN (Edwards and Dim-
mock, 2001). Although SAR1 gave significant PAN with all
viruses, infectivity was reduced by only 50%, with the
exceptions of MN and NL-4.3(R732G). It may be that the
conformation of the SAR1 epitopes of MN and NL-
4.3(R732G) made PAN more efficient. MN has the substi-
tution R751T that could affect the conformation of the
745GERDRDR751 epitope, and NL-4.3(R732G) is known to
have an altered C-terminal tail conformation that allows it to
escape neutralization by an ERDRD-specific polyclonal an-
tibody that gives efficient STAN (McLain et al., 2001). The
R732G substitution, upstream of ERDRD, both abrogated
binding of the selecting antibody and permitted binding of
MAb C8, which before only recognized a denatured form of
734PDRPEG739.
In contrast, neutralization of infectious progeny (NIP)
was more efficient than PAN for all the viruses tested,
except NL-4.3(R732G), although again there was virus-to-
virus variation. The higher levels of NIP suggest that the
epitope on which NIP acts (putatively on nascent gp41 in
the cell membrane or progeny virus) may be better exposed
or in a more appropriate conformation, and is better recog-
nized by SAR1 antibody. It may be significant that viruses
with the lowest NIP titers (NL-4.3(R732G) and MN) had
the highest PAN titers. At this stage it is not clear if PAN
and NIP result from the same or different mechanisms, and
we cannot rule out that NIP may result from PAN of
multiple rounds of nascent gp41 or progeny virus, although
this model does not fit all the data. In summary, SAR1 gave
50% NIP at concentrations from 2 to 26 g/ml, gave lower
levels of PAN, and was largely ineffective at standard neu-
tralization. Further work is needed, particularly to determine
if SAR1 is active against primary virus isolates.
Few, if any, other antibodies behave like SAR1. Its PAN
behavior may be analogous with that of MAb 17b, which
optimally recognizes the gp120 of HIV-1 and neutralizes
infectivity after virions interact with the CD4 receptor
(Thali et al., 1993). However, it is not known if 17b is active
against progeny virus. Antibody to the virion-associated
neuraminidase of influenza A virus inhibits the production
of infectious progeny virus by inhibiting enzyme activity so
that progeny virions bind to the producer cell or other
virions, or by cross-linking and aggregating virions (Seto
and Rott, 1966; Webster et al., 1968; Compans et al., 1969;
Becht et al., 1971; Dowdle et al., 1974). However, unlike
SAR1, which gives little or no STAN, anti-neuraminidase
antibodies are also active against mature virus particles.
MAb 72A1 to Epstein–Barr virus envelope protein gp350/
220 might act in a similar manner to SAR1 as it is reported
to be more effective at inhibiting the release of progeny
virus than neutralizing free virus (Sairenji et al., 1988).
The 745GERDRDR751 epitope
The GERDRDR epitope is situated in the long, ap-
proximately 150-residue C-terminal tail of gp41 that is
conventionally viewed as being entirely inside the virion.
However, we have earlier shown that HIV-1 can be
neutralized in a standard assay by IgG specific to this
epitope (Buratti et al., 1998; Cleveland et al., 2000a,
2003; McLain et al., 2001), and we have argued that,
because this assay uses infectious and therefore intact
virus and because antibody does not cross lipid bilayer
membranes, the GERDRDR epitope of at least some of
the virion gp41 molecules is exposed on the outside of
the virus particle (Cleveland et al., 2003). At least three
different antibodies specific for GERDRDR have been
identified: the epitope-purified polyclonal IgG that gives
standard neutralization (Cleveland et al., 2000a), MAbs
1577 and 1583 that are intrinsically nonneutralizing
(Vella et al., 1993) but neutralize HIV-1 in the presence
of complement (Cleveland et al., 2003), and MAb SAR1
described here that gives poor standard neutralization but
gives PAN and inhibits production of infectious progeny
virus. The fact that SAR1 gives better PAN than STAN
suggests that the SAR1 epitope is more exposed or in a
more compatible conformation after virus– cell interac-
tion than it is in the virion. The binding of SAR1 to all
purified viruses tested (Fig. 3) may mean that the epitope
is for the most part hidden in infectious particles and that
binding is a reflection of the amount of epitope that has
become exposed in broken, noninfectious particles. How-
ever, the fact that IIIB does undergo STAN, albeit inef-
ficiently, suggests that the epitope is exposed/has a
poorly compatible conformation on the outside of infec-
tious virions. Either way it appears that the increase of
PAN over STAN is explained by the SAR1 epitope be-
coming better exposed or changing to a more compatible
conformation after virus binds to cells. SAR1 also bound
to infected cells harvested at 72 h after infection, and this
probably means that it recognizes de novo synthesized
gp41, and hence that the SAR1 epitope is exposed on the
outside of the cell in a SAR1-compatible conformation. It
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is not known if binding of SAR1 to cell surface gp41 is
relevant to SAR1-mediated neutralization of infectious
progeny virus.
In summary, this study suggests that SAR1 IgG may be
unique in terms of its neutralization profile. Our study also
adds to the growing body of evidence that part of the gp41
C-terminal tail is exposed on the outside of the virion
(Cleveland et al., 2000b, 2003; McLain et al., 2001), and
suggests that this region of the tail may be occluded prior to
virus binding to cells, or that it changes conformation after
binding. Further study is needed to clarify what function(s)
the external region of the gp41 tail may have, and if anti-
bodies like SAR1 can make a contribution toward control-
ling HIV-1 infections.
Materials and methods
Viruses and cells
We used the following HIV-1 viruses: IIIB (AIDS Re-
agent Project, NIBSC, Potters Bar, UK); the molecular
clones NL-4.3 (NIH AIDS Research and Reference Reagent
Program) and HxB-2D (AIDS Reagent Project); NL-
4.3(R732G), a mutant that escapes standard neutralization
by an antibody that recognizes the epitope ERDRD in the
C-terminal tail of gp41 (McLain et al., 2001); and HXBH10
and the mutant HXBH10CT that lacks the majority (144
amino acid residues) of the C-terminal tail of gp41 (Mam-
mano et al., 1995). The latter were kindly provided by H.
Go¨ttlinger (Boston, MA, USA). The human T cell lines, H9,
MT4, and C8166 (AIDS Reagent Project), were grown in
RPMI 1640 medium without antibiotics (Gibco BRL, Life
Technologies, Paisley, UK), supplemented with 2 mM glu-
tamine and 10% (v/v) heat-inactivated fetal calf serum
(LabTech International, East Sussex, UK). HIV-1 IIIB, NL-
4.3, and HxB-2D were produced in H9 cells. Medium was
replaced 24 h before harvesting, and virus stored in liquid
nitrogen. HXBH10 and HXBH10CT were grown in MT-4
cells, and assayed in C8166 cells. We also used cowpea
mosaic virus (CPMV) chimeras (donated by T. Jones and
W. Hamilton, Axis Genetics plc, UK) that express short
sequences from the C-terminal tail of gp41 fused with the
small (S) coat protein that are expressed on the external
surface of the virion. Chimera CPMV-HIV/29 expresses
gp41 745GERDRDR751 and CPMV-HIV1 expresses gp41
731PRGPDRPEGIEEEGGERDRDRS752 (Cleveland et al.,
2000a). We also used the wt flock house virus (FHV) coat
protein and fusion proteins that express the gp41 sequences
745GERDRDR751 (FHV-L1-B) or 740IEEEGGERDRDR751
(FHV-L2-A; Buratti et al., 1998). Proteins were produced
by transfecting the relevant plasmids into Escherichia coli
as previously described, purified, and used as described
below (Buratti et al., 1996).
Antibodies
We used the HIV-1 gp41-specific antibodies: mouse
MAb 1575 that is specific to 740IEEE743, mouse MAb 1577
to 746ERDRD750 (Vella et al., 1993) (donated by C. Vella),
and the human MAb 2F5 to amino acids 669ELDKWA674
(Muster et al., 1994) (donated by H. Kattinger and M.
Purtscher), and the gp120-specific rat MAb ICR39.13g
(Cordell et al., 1991) (donated by J. Cordell).
Immunization of mice
Cowpea mosaic virus-HIV-1 gp41 chimera (30 g/ml)
(CPMV-HIV/29; Cleveland et al., 2000a), expressing the
gp41 C-terminal sequence 745GERDRDR751, was mixed
with aluminium hydroxide adjuvant (Imject alum; Pierce &
Warriner Ltd., Chester, UK) and injected subcutaneously
into 10 out-bred To mice (bred in-house) on days 0 and 22.
Blood was obtained from the tail 7 days later. After testing
for neutralizing and GERDRDR-specific antibody by
ELISA, one mouse was immunized with 30 g CPMV-
HIV/29 intravenously to provide splenocytes. All work fol-
lowed the guidelines of the UK Co-ordinating Committee
for Cancer Research.
Production of hybridomas
Four days after final immunization, the selected mouse
was culled and splenocytes were prepared. Splenocytes and
Sp2 cells (10:1) in serum-free alpha-MEM (GibcoBRL,
Life Technologies, Paisley, UK) were fused using 30%
polyethylene glycol (PEG) and plated out under standard
selection with hypoxanthine, aminopterin, and thymidine in
medium containing 10% fetal calf serum. Tissue culture
fluids (TCFs) were tested after 14 days for ELISA reactivity
with the flock house virus fusion protein, FHV-L2-A. Cells
from positive wells were subjected to three sets of limiting
dilution to ensure clonality. After expansion, cells were
frozen in liquid nitrogen. IgG from TCF was purified using
Gammabind plus protein G-Sepharose (Pharmacia Biotech
Ltd., St. Albans, UK), and the isotype determined (RPN 29;
Amersham Pharmacia Biotech Ltd., UK).
Determination of IgG concentration by ELISA
Serial dilutions of purified IgG were captured with im-
mobilized goat anti-mouse IgG. Capture IgG (-chain spe-
cific; Sigma, UK) at 0.1 g/well in 100 mM sodium bicar-
bonate buffer, pH 8.5, was bound to ELISA plates
(Immunolon-2, Dynal, ThermoLife Sciences, Basingstoke,
UK) overnight at 4°C. Plates were blocked with 3% defatted
dried milk (Marvel, UK). Bound mouse IgG was detected
by successive incubation with biotinylated sheep anti-
mouse IgG (Amersham Pharmacia Biotech Ltd., UK),
streptavidin conjugated with alkaline phosphatase (Amer-
sham Life Science, UK), and p-nitrophenyl phosphate
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(Sigma). The IgG concentration was interpolated from a
standard curve of mouse IgG against OD405.
Reactivity of SAR1 with antigens carrying the gp41
GERDRDR sequence
ELISA reactivity was determined with the chimeras
CPMV-HIV/29 (745GERDRDR751) and CPMV-HIV/1
(731PRGPDRPEGIEEEGGERDRDRS752), the fusion pro-
teins FHV-L2-A (740IEEEGGERDRDR751) and FHV-L1-B
(745GERDRDR751), the gp41 Kennedy peptide (731PRGP-
DRPEGIEEEGGERDRDRS752), and wt CPMV that dis-
plays no HIV-1 epitope. ELISA plates were then coated
with the CPMV chimeras, the FHV fusion proteins, and the
peptide to give approximately equivalent molar amounts of
bound ERDRD. The actual amount of antigen bound was
then determined by titration with specific antibody: CPMV-
HIV/1, FHV-L-2A, and peptide with MAb 1575, FHV-L-
2A, and FHV-L-1B with FHV-specific polyclonal IgG, and
CPMV-HIV/1 and CPMV-HIV/29 with wt CPMV-specific
polyclonal antibody. Antigens were applied in bicarbonate
buffer at the following concentrations: chimeras (0.1 g/
well), FHV proteins (0.03 g/well), and peptide (0.002
g/well), and after blocking the plate, were reacted with a
range of SAR1 concentrations (0.0001–10 g) to determine
the linear part of the response curve. Bound antibody was
detected as described for IgG determination above.
Western blots of HIV-1 IIIB polypeptides
HIV-1 IIIB was purified from the tissue culture fluid
(TCF) of H9 cells by differential centrifugation and the
virus pellet denatured in reducing buffer at 56°C for 1 h.
Samples (containing 1.6  104, 8  103, or 4  103
syncytium-forming units (sfu) per lane) were then electro-
phoresed on a 10% SDS–PAGE gel and transblotted onto a
nitrocellulose membrane (Hybond C, Amersham Life Sci-
ences Ltd., UK). The nitrocellulose was blocked with 10%
marvel in phosphate-buffered saline (PBS) with 0.1%
Tween 20 (PBS-T) overnight at 4°C and incubated with
purified IgG (10 g/ml) in 3% Marvel defatted milk (Pre-
mier Brands Ltd, Spalding, UK) in PBS-T for 1 h at room
temperature. Bound IgG was detected with HRP-conjugated
anti-mouse IgG (Biorad Microsciences Ltd., UK) and 3,
3-diaminobenzidine (Sigma, UK).
Reactivity of IgGs with purified HIV-1
Various strains of HIV-1 (NL-4.3, NL-4.3(R732G), IIIB,
or HxB-2D) were purified by differential centrifugation and
banded on a 15–60% sodium-potassium tartrate gradient
(87,000g for 16–18 h at 4°C). The virus pellet was col-
lected, resuspended in PBS, and fixed with 2% paraformal-
dehyde (BDH Chemicals, Poole) overnight at 4°C. Virus
(105 sfu/well) was captured on wells that had been coated
with 0.1 g human MAb 2F5 in 100 l bicarbonate buffer
overnight at 4°C. The plate was then washed and incubated
with a range of concentrations (0.03–10 g/well) of MAb
SAR1 IgG or with the gp120-specific MAb ICR39.13g IgG
as a positive control. The negative control used 10 g/ml
normal mouse serum IgG. All antibodies were in PBS and
100 l volumes. Reactions were for 1 h at room tempera-
ture. Bound IgGs were detected by ELISA using biotinyl-
ated rabbit anti-mouse IgG as described above.
Reactivity of IgGs with HIV-1-infected cells
C8166 cells (106) were infected with NL-4.3, NL-
4.3(R732G), IIIB, or HxB-2D (0.01 sfu/cell) for 72 h at
37°C. After washing these were fixed in 2% paraformalde-
hyde in PBS overnight at 4°C. U-bottomed microtiter plates
(Greiner, Labortechnik Ltd., Gloucestershire, UK) were
blocked with 3% marvel in PBS-T and rehydrated fixed
cells aliquotted at 5  104 cells/well. SAR1, 1575, or
normal mouse serum IgGs (10 g/ml) were reacted with
pelletted cells for 1 h at room temperature. After washing,
bound IgG was detected with HRP-conjugated anti-mouse
IgG and o-phenylenediamine according to the manufactur-
er’s instructions (Sigma, UK).
Standard neutralization assay
A previously described assay was used (McLain and
Dimmock, 1994). Briefly C8166 cells (2  104/well) were
immobilized 96-well microtiter plates coated with 2.5 g/
well poly-L-lysine. Virus (400 sfu in 200 l) was incubated
with an equal volume of antibody for 1 h at 37°C. Cells
were inoculated with virus–antibody/medium mixture (50
l) for 1 h at 37°C, the inoculum was removed, and medium
(200 l/well) was added for 72 h at 37°C. Neutralization
was expressed as the percentage reduction in syncytium
count (five replicates) in wells containing the virus–anti-
body mix compared to that of the virus control without
antibody.
Postattachment neutralization (PAN) assay
This assay is designed to permit neutralization by anti-
body only after virus has attached to cells. Immobilized
C8166 cells (see above) were inoculated with 50 sfu in 50
l for 1 h at 4°C or room temperature. The inoculum was
then discarded and replaced with serial dilutions of antibody
(200 l/well in five replicates) and the plate incubated for
72 h at 37°C. PAN was measured as the percentage reduc-
tion in syncytium count in the antibody treated wells com-
pared to that of the virus control without antibody.
Neutralization of infectious progeny virus (NIP) assay
TCFs from the PAN assay above at 72 h after infection
were titrated for the presence of infectious progeny virus on
C8166 cells (five replicates). After allowing virus to attach
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to cells for 1 h at 37°C, cells were washed three times, and
medium was added. Syncytia were counted 3 days later.
NIP was calculated as the percentage reduction of the yield
of virus in the presence of antibody compared with the yield
of virus in the absence of antibody.
Mapping of the SAR1 epitope by competitive inhibition of
binding to FHV-L2-A
MAb 1575 IgG (specific for the gp41 epitope
740IEEE743) was biotinylated using a sulfo-NHS-biotin kit
according to the manufactures guidelines (Pierce). Biotin-
ylated MAb 1575 (0.2 g) was mixed with MAb SAR1,
MAb 1577 (746ERDRD750-specific), or normal mouse se-
rum IgG (all at 0.03 to 3.0 g) and incubated for 1 h at 37°C
with immobilized FHV-L2-A (bound at 0.1 g/well).
Bound 1575 IgG was detected by ELISA with biotinylated
rabbit anti-mouse IgG as described above.
Mapping of the SAR1 epitope by competitive inhibition of
PAN
MAb 1575 (see above) is nonneutralizing, and here we
used its ability to interfere with PAN mediated by SAR1 to
locate the position of the SAR1 epitope. Immobilized
C8166 cells were inoculated as in the PAN assay above,
followed 1 h later by MAb SAR1 (20 g/well) mixed with
MAb 1575 (0.0002, 0.002, 0.02, 0.2, or 20 g/well), SAR1
(20 g/well), or 1575 alone (20 g/well) as a negative
control. PAN was recorded as before.
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